Patent Assignment
Reel/Frame 055056/0891
Release of Security Interest
Recorded: 2021-01-21
Pages: 49
Assignor
WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Executed: 2021-01-08
Assignee
WELLSTAT THERAPEUTICS CORPORATION
14200 SHADY GROVE ROAD, SUITE 600, ROCKVILLE, MARYLAND, 20850
Covered Properties
(99)
Aerobic Wastewater Management System, Apparatus, and Method
PCT:
PCT/US2006/001205 ↗
3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
PCT:
PCT/US2012/028723 ↗
Stem Cell Mobilization and Tissue Repair and Regeneration
PCT:
PCT/US2012/038610 ↗
Treatment of Chemotherapeutic Agent and Antiviral Agent Toxicity with Acylated Pyrimidine Nucleosides
Patent:
7,776,838 →
Application:
08/460,186 →
Inhibitor of Stem Cell Proliferation and Uses Thereof
Compounds for the Treatment of Metabolic Disorders
Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Heptitis
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
The Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the treatment of metabolic disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Application:
10/865,088 →
Publication:
US 2004/0242692
Compounds for the Treatment of Metabolic Disorders
Inhibitor of stem cell proliferation and uses thereof
Application:
10/897,005 →
Publication:
US 2005/0043218
Compound for the treatment of metabolic disorders
Methods for the Treatment of Metabolic Disorders Such as Diabetes
Compounds for the Treatment of Metabolic Disorders
Application:
11/772,501 →
Publication:
US 2007/0249696
Method for the Treatment of Metabolic Disorders
Method for the Treatment of Metabolic Disorders
Application:
11/772,511 →
Publication:
US 2007/0249719
Method for the Treatment of Metabolic Disorders
Application:
11/772,515 →
Publication:
US 2007/0244171
Method for the Treatment of Metabolic Disorders
Application:
11/772,520 →
Publication:
US 2007/0244141
Method for the Treatment of Metabolic Disorders
Application:
11/772,556 →
Publication:
US 2007/0265323
Method for the Treatment of Metabolic Disorders
Method for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Application:
11/841,508 →
Publication:
US 2008/0015209
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Access Control to Partitioned Blocks in Shared Memory
Application:
11/909,121 →
Publication:
US 2009/0254713
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Application:
12/162,397 →
Publication:
US 2009/0176885
Compositions for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Application:
12/279,808 →
Publication:
US 2010/0227901
Combination Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Application:
12/304,007 →
Publication:
US 2010/0234464
Combination Treatment for Metabolic Disorders
Application:
12/377,460 →
Publication:
US 2010/0227809
Compounds for the Treatment of Metabolic Disorders
Hemoglobin Alpha Chain Peptide Fragments Useful for Inhibiting Stem Cell Proliferation
Application:
12/534,675 →
Publication:
US 2010/0041147
Method for the Treatment of Metabolic Disorders
Compounds for the Treatment of Metabolic Disorders
Compounds and Method for Reducing Uric Acid
Tetrazole Compounds for Reducing Uric Acid
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Compounds for the Treatment of Metabolic Disorders
Application:
13/034,201 →
Publication:
US 2011/0166233
Synthesis of (Phenylalkyloxy)Phenyl-Oxobutanoic Acids
Compounds for the Treatment of Metabolic Disorders
Application:
13/217,977 →
Publication:
US 2012/0071526
Determining the Severity of 5-Fluorouracil Overdose
Application:
13/319,563 →
Publication:
US 2012/0078529
3-Substituted Compounds for Reducing Uric Acid
Combination Treatment for Metabolic Disorders
Application:
13/749,135 →
Publication:
US 2013/0137629
Tetrazole Compounds for Reducing Uric Acid
Benzoic Acid Compounds for Reducing Uric Acid
Application:
13/821,402 →
Publication:
US 2013/0331452
Compounds for the treatment of metabolic disorders
Application:
60/297,282 →
Compounds for the treatment of metabolic disorders
Application:
60/423,253 →
Compounds for the treatment of metabolic disorders
Application:
60/447,168 →
Compounds for the treatment of metabolic disorders
Application:
60/462,960 →
Compounds for the treatment of metabolic disorders
Application:
60/464,553 →
Compounds for the treatment of metabolic disorders
Application:
60/466,663 →
Compounds for the treatment of metabolic disorders
Application:
60/496,533 →
Compounds for the treatment of metabolic disorders
Application:
60/667,457 →
Compounds for the treatment of metabolic disorders
Application:
60/734,803 →
Combination Treatment of Metabolic Disorders
Application:
60/744,021 →
Compounds for the Treatment of Metabolic Diseases
Application:
60/747,638 →
Compounds for the treatment of metabolic disorders
Application:
60/762,066 →
Compounds for the treatment of metabolic disorders
Application:
60/762,068 →
Compounds for the treatment of metabolic disorders
Application:
60/762,091 →
Compounds for the treatment of metabolic disorders
Application:
60/764,544 →
Compounds for the treatment of metabolic disorders
Application:
60/772,687 →
Compounds for the treatment of metabolic disorders
Application:
60/777,678 →
Compounds for the Treatment of Metabolic Disorders
Application:
60/804,336 →
Combination Treatment for Metabolic Disorders
Application:
60/822,676 →
Compounds for the Treatment of Metabolic Disorders
Application:
61/021,061 →
Compounds and Method for Reducing Uric Acid
Application:
61/036,294 →
Tetrazole Compounds for Reducing Uric Acid
Application:
61/049,167 →
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Application:
61/050,442 →
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Application:
61/057,410 →
Tetrazole Compounds for Reducing Uric Acid
Application:
61/093,743 →
Compounds for the Treatment of Metabolic Disorders
Application:
61/096,576 →
Synthesis of (Phenylalkyloxy)Phenyl-Oxobutanoic Acids
Application:
61/111,133 →
Determining the Severity of 5-Fluorouracil Overdose
Application:
61/177,890 →
3-Substituted Compounds for Reducing Uric Acid
Application:
61/251,098 →
Benzoic Acid Compounds for Reducing Uric Acid
Application:
61/380,882 →
3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
Application:
61/452,410 →
Stem Cell Mobilization and Tissue Regeneration
Application:
61/487,548 →
Stem Cell Mobilization and Tissue Repair and Regeneration
Application:
61/728,058 →
Stem Cell Mobilization and Tissue Repair and Regeneration
Application:
61/735,227 →
Amine Compounds Having Antiparasitic Activity
Application:
61/759,512 →
Related Assignments
(10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Aug 19, 2002
From: SHARMA, SHALINI; VON BORSTEL, REID W.; HODGE, KIRVIN L.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 013219/0513 →
Assignment of Assignor's Interest
Jun 18, 2003
From: TSYRLOVA, IRENA; WOLPE, STEPHEN D.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 014187/0730 →
Assignment of Assignor's Interest
Dec 12, 2003
From: SHARMA, SHALINI; VON BORSTEL, REID W.; HODGE, KIRVIN L.; BAMAT, MICHAEL K.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 015534/0374 →
Assignment of Assignor's Interest
Mar 21, 2006
From: VENTURE MANAGEMENT ALLIANCE LLC
To: CDC INVESTMENTS, LLLP
Reel/Frame 017707/0189 →
Security Agreement
Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →
Security Agreement
Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
Assignment of Assignor's Interest
Jun 16, 2014
From: TSYRLOVA, IRENA; PETTY, FAWN; VON BORSTEL, REID W.; READING, JULIAN
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 033107/0359 →
Release of Certain Intellectual Property Collateral Owned by Wellstat Therapeutics Corporation Recorded at Reel 031227/Frame 0227
Jun 30, 2023
From: PDL BIOPHARMA, INC.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 064180/0456 →
Assignment of Assignor's Interest
Nov 6, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 065474/0475 →
Assignment of Assignor's Interest
Oct 30, 2024
From: WELLSTAT THERAPEUTICS CORPORATION
To: BTG INTERNATIONAL INC.
Reel/Frame 069079/0028 →